Skip to main content

Table 4 Human recombinant MAO inhibitory profile of eugenol based derivatives

From: Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study

Compound/sample

IC50 (µM)a hMAO-A

IC50 (µM)a hMAO-B

Selectivity indexb

Docking score hMAO-A

Docking score hMAO-B

5a

15.85 ± 0.039

29.37 ± 0.048

0.53

− 9.65

− 3.23

5b

5.989 ± 0.007

31.19 ± 0.016

0.19

− 12.57

− 3.98

7

10.46 ± 0.072

43.31 ± 0.043

0.24

− 11.45

− 1.76

9a

10.84 ± 0.025

47.70 ± 0.073

0.22

− 11.34

− 1.01

9b

16.62 ± 0.004

27.85 ± 0.054

0.59

− 8.99

− 6.45

11

18.06 ± 0.044

26.80 ± 0.077

0.67

− 7.34

− 5.34

13a

38.53 ± 0.018

7.494 ± 0.014

5.14

− 2.45

− 11.87

13b

52.55 ± 0.038

9.183 ± 0.034

5.72

− 1.09

− 10.45

13c

22.38 ± 0.067

12.66 ± 0.021

1.76

− 6.45

− 10.32

13d

20.89 ± 0.023

13.95 ± 0.005

1.49

− 5.32

− 9.99

16

7.348 ± 0.027

49.15 ± 0.011

0.14

− 11.98

− 2.21

17

13.92 ± 0.051

34.20 ± 0.037

0.40

− 9.99

− 4.23

Eugenol

16.54 ± 0.045

13.30 ± 0.037

1.24

− 6.46

− 7.82

Pargyline

20.04 ± 0.095

− 6.061

Chlorgyline

18.74 ± 0.096

− 5.773

  1. aValues related for the evaluated compound absorption which provide 50% inhibition of MAO-A and MAO-B, action, and are the mean SEM; statistical significance: p < 0.05 against the equivalent IC50 values achieved against MAO-A and MAO-B, as identified through ANOVA/Dunnett’s test
  2. bSelectivity index = IC50 (MAO-A)/IC50 (MAO-B)